SEAGEN INC. CORAL SPRINGS, Florida, July 16, 2014 /PRNewswire/ --
Biotechnology Companies strive to improve cancer treatment and develop innovative therapies as biotech sector sees growth as well as registered success: GenSpera, Inc. (OTC: GNSZ), Codexis, Inc. (NASDAQ: CDXS), Eli Lilly and Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Seattle Genetics (NASDAQ: SGEN).
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5th Asia-Pacific Primary Liver Cancer Expert Meeting Saturday, July 12th, in Taipei, Taiwan.
Dr. Mahalingam, an oncologist at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio, presented interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of, sorafenib. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study.
Read this FULL GNSZ press release at http://www.fnmprofiles.com/profiles-gnsz.html
"The efficacy and safety analyses on patients enrolled to date on this study continue to demonstrate that G-202 holds promise for patients with advanced HCC, with half the patients showing disease stability at 4 months and the majority of patients tolerating G-202 with minimal toxicities," stated Dr. Mahalingam.
GenSpera also recently announced that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company.
GNSZ is attractive for speculative accounts seeking above-average appreciation potential based upon the considerations listing in the full report. Based on the company's attractive growth prospects with a pipeline of products based upon its unique platform targeting large tumor applications; and strong development and experienced management team that has taken drugs successfully through clinical trials, we recommend the purchase of GNSZ stock for speculative accounts seeking long-term capital appreciation. Kareg's target more than a double within the next 12-24 months. Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf
Codexis, Inc. (NASDAQ: CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the signing of a platform technology license agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, Codexis granted GSK a license to use Codexis' proprietary CodeEvolver(R) protein engineering platform technology in the field of human healthcare. The license allows GSK to use Codexis' platform technology to develop novel enzymes for use in the manufacture of GSK's pharmaceutical and health care products. GSK may also use the licensed technology to develop new therapeutic, diagnostic and prophylactic products in the human health field. Upon completion of technology transfer, GSK will have Codexis' state-of-the-art CodeEvolver protein engineering platform installed at its Upper Merion, Pennsylvania research and development site.
Eli Lilly and Company (NYSE: LLY) has rebooted the Lilly for Better Health(TM) program, with several innovative enhancements to lillyforbetterhealth.com that help enrich the user experience with Lilly's non-product-branded health education. Changes to the site include improved ease of use, interactive engagement and an updated mobile experience. Lilly for Better Health is one of the many ways Lilly goes beyond medicine to support individuals and caregivers on their health care journeys. The program, and its website, lillyforbetterhealth.com, recognized by the MarCom Awards, Aster Awards and eHealthcare for excellence in health communication, offer nearly 100 non-product-branded health education resources in English and Spanish, plus information on health-related topics, such as diabetes, depression, exercise and stress.
Pfizer Inc. (NYSE: PFE) recently announced the opening of a new 280,000 square-foot Research and Development (R&D) hub in Cambridge, Mass. The new Pfizer facilities in Kendall Square bring together 1,000 colleagues from three area locations and position Pfizer in closer proximity to leading academic institutions, hospitals and patient organizations. "Our new Kendall Square presence in Cambridge represents an important milestone in Pfizer's approach to creating a sustainable R&D engine that is designed to yield a flow of innovative therapies year after year," said Mikael Dolsten, M.D., Ph.D., President of Worldwide Research and Development at Pfizer. "Having all of our Cambridge-area researchers working closely together in one of the world's most exciting biomedical ecosystems will allow us to continue our efforts to grow our external collaborations and has the potential to help speed the translation of scientific knowledge into potential medical breakthroughs across areas of unmet need such as lupus, inflammatory bowel disease, kidney disease, type 2 diabetes, muscular dystrophy and Parkinson's disease."
Johnson & Johnson (NYSE: JNJ) recently announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%. Domestic sales increased 14.9%. International sales increased 4.4%, reflecting operational growth of 5.0% and a negative currency impact of 0.6%. Net earnings and diluted earnings per share for the second quarter of 2014 were $4.3 billion and $1.51, respectively. The second-quarter results included a charge for after-tax special items of approximately $0.4 billion, primarily related to an increase in the litigation accrual as well as integration and transaction costs related to the acquisition of Synthes, Inc. Second quarter 2013 net earnings included a charge for after-tax special items of approximately $0.5 billion as shown in the accompanying reconciliation of non-GAAP financial measures. To read the full report, please click here: http://finance.yahoo.com/news/johnson-johnson-reports-2014-second-114500172.html
Seattle Genetics (NASDAQ: SGEN), a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that has been approved in approximately 35 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. On Tuesday, SGEN closed down 4.66% on over 1.5 million shares traded.
FinancialNewsMedia.com [http://www.financialnewsmedia.com ] is leading provider of third party publishing & news dissemination services [http://financialnewsmedia.com/products-services.php ]. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts [http://www.financialnewsmedia.com/emailsubmit.php ] that are FREE for a limited time at http://www.financialnewsmedia.com/ [http://www.financialnewsmedia.com/emailsubmit.php ]. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand four hundred dollars for news coverage of the current press release issued by GenSpera, Inc. by the company.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
Contact Information:
Company: FN Media Group, LLC [http://www.financialnewsmedia.com ]
Contact email: editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.comSOURCE FN Media Group LLC
